Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (241-250 of 377) with videos related to

Pageof 38
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2014
Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for ¹⁸F-FDG Brain Imaging in Patients Examined for Suspected DementiaStefan Hitz, Cornelia Habekost, Sebastian Fürst, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2026
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolizationLisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2026
AI-based tumor and organ volumetry predicts early progression after Y-90 radioembolization in liver-dominant metastatic diseaseDaniel Martinez Heinemann, Jannis Bodden, Lukas Endroes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2013
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancerMichael Souvatzoglou, Matthias Eiber, Toshiki Takei, et al.
Asian Journal of Urology|February 24, 2022
Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancerChrista Babst, Thomas Amiel, Tobias Maurer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective StudyAndrea Farolfi, Nader Hirmas, Andrei Gafita, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2021
Whole-body uptake classification and prostate cancer staging in <sup>68</sup>Ga-PSMA-11 PET/CT using dual-tracer learningNicolò Capobianco, Ludovic Sibille, Maythinee Chantadisai, et al.
Oncotarget|August 31, 2016
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomySarah M Schwarzenböck, Anna Knieling, Michael Souvatzoglou, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
European Urology|November 27, 2018
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup>Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerMatthias M Heck, Robert Tauber, Sebastian Schwaiger, et al.
Pageof 38

Showing results (241-250 of 377) with videos related to

Sort By:
Pageof 38
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2014
Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for ¹⁸F-FDG Brain Imaging in Patients Examined for Suspected DementiaStefan Hitz, Cornelia Habekost, Sebastian Fürst, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2026
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolizationLisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2026
AI-based tumor and organ volumetry predicts early progression after Y-90 radioembolization in liver-dominant metastatic diseaseDaniel Martinez Heinemann, Jannis Bodden, Lukas Endroes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2013
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancerMichael Souvatzoglou, Matthias Eiber, Toshiki Takei, et al.
Asian Journal of Urology|February 24, 2022
Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancerChrista Babst, Thomas Amiel, Tobias Maurer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective StudyAndrea Farolfi, Nader Hirmas, Andrei Gafita, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2021
Whole-body uptake classification and prostate cancer staging in <sup>68</sup>Ga-PSMA-11 PET/CT using dual-tracer learningNicolò Capobianco, Ludovic Sibille, Maythinee Chantadisai, et al.
Oncotarget|August 31, 2016
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomySarah M Schwarzenböck, Anna Knieling, Michael Souvatzoglou, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
European Urology|November 27, 2018
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup>Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerMatthias M Heck, Robert Tauber, Sebastian Schwaiger, et al.
Pageof 38